The Effect of Environmental Pollution on Colorectal Cancer

November 12, 2024 updated by: Dong Peng

Clinical Study of the Effect of Environmental Pollution on the Prognosis of Colorectal Cancer.

Colorectal cancer (CRC) is one of the most common malignancies worldwide, and its main risk factors include age, genetic factors, inflammatory bowel diseases (e.g., ulcerative colitis and Crohn's disease), unhealthy diets (e.g., high-fat, low-fibre diets), obesity, physical inactivity, smoking, and excessive alcohol consumption. The relationship between environmental pollution and colorectal cancer has received increasing attention in recent years. Studies have shown that long-term exposure to fine particulate matter in the air, such as passive smoking, soot and oil smoke exposure, incense burning exposure, occupational exposure and outdoor work, PM2.5, PM10 and NO2 may increase the risk of colorectal cancer. These particulate matter can enter the lungs through breathing and trigger a chronic inflammatory response in the systemic system, thus increasing the risk of cancer development. This study intends to determine the extent of air pollution's impact on colorectal cancer prognosis by analysing survival data of colorectal cancer patients in regions with different pollution levels. As well as to investigate the association between air pollution levels and postoperative recurrence in colorectal cancer patients, looking for possible mechanisms.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

6300

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients diagnosed as colorectal cancer

Description

Inclusion Criteria:

  • age ≥18 years;
  • patients diagnosed with colorectal cancer by pathological biopsy before surgery;
  • patients did not undergo chemotherapy, radiotherapy, targeted and immunotherapy, etc. before enrolment;
  • willing to participate in this study and sign an informed consent form;
  • complete clinical data.

Exclusion Criteria:

  • patients with primary malignant tumours other than colorectal cancer;
  • patients with systemic diseases, such as severe cardiopulmonary insufficiency, that affect the choice of treatment options;
  • patients who are not suitable for enrolment as assessed by the investigator;
  • incomplete clinical data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
the colorectal cancer group
patients diagnosed as colorectal cancer

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
colorectal cancer
Time Frame: From 18 years old until the developing colorectal cancer, through study completion, an average of 5 year.
the time for diagnosing colorectal cancer
From 18 years old until the developing colorectal cancer, through study completion, an average of 5 year.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Dong Peng

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2010

Primary Completion (Actual)

November 1, 2024

Study Completion (Actual)

November 1, 2024

Study Registration Dates

First Submitted

November 12, 2024

First Submitted That Met QC Criteria

November 12, 2024

First Posted (Estimated)

November 13, 2024

Study Record Updates

Last Update Posted (Estimated)

November 13, 2024

Last Update Submitted That Met QC Criteria

November 12, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ZZ2024-291-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Clinical centres conducting this study are not allowed to disclose patient information and data sharing.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Colorectal Carcinoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe